Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The company's HBV-cure program is focused on advancing a new class of potent, oral core inhibitors that have the potential to cure HBV. Assembly also has a robust microbiome program with multiple preclinical and clinical-stage oral live biotherapeutic candidates in development for both gastrointestinal and non-gastrointestinal indications. Assembly is headquartered in Carmel, Indiana and has offices in San Francisco, California.